As of September 30, 2019, Odonate had $204.2 M in cash, contrast to $139.1 M since December 31, 2018. This increase in cash resulted mainly from the invoice of $135.1 M of net profits from Odonates June 2019 underwritten public offering, less net money used in running activities of $72.1 M. Odonates bottom line for the 3 and nine months ended September 30, 2019 was $26.6 M and $84.0 M, or $0.88 and $3.15 per share, respectively, contrast to $23.9 M and $60.2 M, or $0.98 and $2.47 per share, respectively, for the very same periods in 2018.
” We more than happy to have recently reported the conclusion of registration in CONTESSA, Odonates Phase 3 research study examining tesetaxel as a potential treatment for clients with metastatic breast cancer,” mentioned Kevin Tang, Chief Executive Officer of Odonate. “We expect to report top-line outcomes from CONTESSA in the 3rd quarter of 2020.”
ODT is tape-recorded at 1.96 and the relative strength index of the stock stands 59.96. The stock rate is trading upbeat from its 200 days moving typical with 23.00% and up from 50 days moving typical with 12.84%.
Odonate Therapeutics, Inc. (ODT) recently reported financial results for the three and nine months ended September 30, 2019.
On Monday, Odonate Therapeutics Inc (NASDAQ: ODT) stock traded volume of 114847 shares throughout its last trading session as compared to its average volume of 108142 shares over the current month. ODT ended its day with the above stream along the move of 3.39% and closed at the rate of $32.59 prior to opening at $31.32. It has overall market capitalization is $1045617564. 52-week variety of the stock stayed $11.54 – 43.75 while its day most affordable rate was $29.92 and its hit its day highest cost at $32.92.